TDENV-PIV / GSK, U.S. Army Medical Research and Development Command - LARVOL DELTA

Tracing down the Updates on Dengue Virus-Molecular Biology, Antivirals, and Vaccine Strategies. (PubMed, Vaccines (Basel)) - "There is a need to put more effort into developing effective vaccines and therapeutics for dengue, as already approved vaccines and therapeutics have limitations. DENGVAXIA is approved for use in children and teenagers who are 6-16 years of age and have confirmed dengue infection, while Takeda is approved for use in certain countries, and it has withdrawn its application for FDA approval."

Journal • Review • Dengue Fever • Infectious Disease